Lv3
300 积分 2023-11-03 加入
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
17天前
已完结
IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results
25天前
已关闭
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
1个月前
已完结
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
1个月前
已完结
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
1个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
1个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
1个月前
已完结
Antibody-bottlebrush prodrug conjugates for targeted cancer therapy
1个月前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
1个月前
已完结
Rapidly separable bubble microneedle-patch system present superior transdermal mRNA delivery efficiency
1个月前
已完结
皖公网安备34019202002308
